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Abstract
Purpose Microwave ablation (MWA) is an accepted technique in the multimodal treatment of hepatocellular carcinoma (HCC)
and colorectal liver metastases (CRLM). Study endpoints were to evaluate the local efficacy of surgicalMWA in selected patients
with oligonodular disease without the combination of liver resection to allow a clear interpretation of the follow-up imaging and
compare it to the results on percutaneous MWA available in the literature.
Methods ConsecutiveMWA-only procedures performed betweenMay 2013 andMay 2018 for HCC and CRLMwith free-hand
ultrasound guidance were identified. MWA systems with 2450MHz were used. Incomplete ablation (IA) was defined as residual
disease within 1 cm of the ablation site at the first post-ablation imaging and local recurrence (LR) as the presence of disease after
at least one tumor-free imaging.
Results A total of 70 tumors in 47 patients were treated with 46 laparoscopic and 1 open procedures. Each patient had no more
than 3 tumors, and median size of the lesions was 15mm (IQR: 10–22). After a median follow-up of 26months (IQR: 12–40), IA
rate was 8.6% and LR rate was 29.4%. Multivariable analysis showed that vascular proximity (OR = 3.4; 95% CI = 1.26–9.22;
p=0.016) was the only significant predictor of the combined outcome IA or LR.
Discussion In the present study, after mostly laparoscopic MWA, LR was higher than the rates available in the literature for
percutaneous MWA of HCC but lower than in the limited studies analyzing isolated percutaneous MWA of liver metastases.
Future developments may help establish the role of each therapeutic modality per tumor, in order to improve the outcomes.
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Introduction
Ablation techniques provide an extra tool in the treatment of
hepatic tumors by allowing a shorter and less morbid proce-
dure. It is an attractive option for patients in a poor clinical
state or with a more reserved oncologic prognosis, which
would not warrant a riskier resection. The most frequent indi-
cations for liver surgery and thermal ablation are hepatocellu-
lar carcinoma (HCC) and colorectal liver metastases (CRLM).
Ablations can be combined with liver resections in a
parenchyma-preserving approach for CRLM [1, 2].
Unfortunately, this comes at the cost of a higher local recur-
rence rate than surgery, which remains the gold standard [3].
Radiofrequency ablation (RFA) is effective in the treatment of
HCC although not superior to surgery [4, 5]. Microwave ab-
lation (MWA), with its higher energy, generates higher tem-
peratures in a shorter period of time and seems to provide a
better local control than RFA, with less blood driven heat sink
effect and permitting to target larger lesions [1, 6].
Percutaneous ablations offer a minimally invasive option
for the local treatment of hepatic malignancies with low mor-
bidity and possibility of CT guidance to target lesions barely
visible with ultrasound [7]. Their therapeutic role in the treat-
ment of very early and early stage HCC has been broadened
from patients ineligible for a hepatectomy to an alternative to
liver resection until the possibility of being adopted as first-
line therapy according to the current European Association for
the Study of the Liver clinical practice guidelines [7]. There is
less experience with the local efficacy of isolated MWA for
CRLM in comparison to HCC [8].
In the quest for minimally invasive treatment options for
hepatic malignancies, the choice between hepatectomy and
ablation can be made after weighing the morbidity of the pro-
cedure against the expected efficacy according to the residual
liver function, location of the lesion, and comorbidities of the
patient [3–5]. If an ablation is preferred, the choice still has to
be made between a CT-guided percutaneous procedure and
intraoperative ablation with an open or laparoscopic approach.
In order to establish the role of each modality of ablation, their
local efficacy should be known and compared.
The evaluation of the results of hepatic ablation is challeng-
ing when this is combined with hepatic resections, making it
difficult to discern which outcomes precisely derive from ther-
mal ablation. A postoperative hypodensity on imaging can
correspond to the expected ablation zone, or it can indicate
an ischemic area caused by a neighboring resection. In com-
bined hepatic procedures, it also becomes more complex to
differentiate between a local or “de novo” hepatic recurrence.
Marginal hyperemia around the ablation zone can be seen in
the early phases post-ablation, and this finding can be mistak-
en for residual tumor. Sequential imaging analysis before and
after the ablation is essential. The first cross-sectional imaging
after thermal ablation should not show suspect contrast
enhancement in the ablation zone and should display enough
overlap by having a wider diameter than the original lesion, in
order to be considered a complete ablation. The detection of
asymmetric contrast enhancement in ulterior imaging or in-
crease in diameter of the ablation zone is considered as suspect
for a local recurrence (LR) [9].
Several predictive factors for incomplete ablation (IA) or
LR have been proposed in literature such as etiology (HCC
versus CRLM), location in the posterosuperior segments (seg-
ments 1, 4a, 7, 8), tumor size, vascular proximity, superficial
location, and requirement of multiple ablations of the same
lesion [1, 10].
In order to evaluate the efficacy of MWA on the local
control of liver tumors and to identify predictive factors for
IA and LR, we retrospectively reviewed the patients with
HCC and CRLM, treated in Ghent University Hospital with
sole surgical MWA without combination with liver resection
or any other type of procedure. We compared the results with
the available literature on percutaneous MWA.
Material and methods
Patient selection and collection of data
In this retrospective single-center study, all consecutive pa-
tients who underwent a surgical MWA with curative intent
for HCC and CRLM at the Ghent University Hospital be-
tween May 2013 and May 2018 were identified, based on
the review of clinical files and operation records. Patients with
combined procedures were excluded in order to better evalu-
ate the local effects of the ablation, the postoperative course,
and the efficacy of the local control throughout follow-up. All
patients were discussed at a multidisciplinary oncology meet-
ing where the surgical indication and therapeutic modality
were agreed upon. Whenever possible, surgical resection of
the tumors was preferred. Patients were selected for ablation in
case of cirrhosis with anticipated high-risk hepatectomy for
liver failure or in case of extensive surgical or medical history
that favored a less invasive approach. The indication for intra-
operative ablation was established preoperatively. The study
protocol and all the procedures were performed according to
the institutional ethical standards of Ghent University Hospital
(reference number: B67020173366). The data collected in-
cluded demographics, details on the surgical procedure and
postoperative period, morbidity, mortality, characteristics of
the hepatic lesions, and iconography.
Study endpoints
The primary endpoint of the study was to evaluate the efficacy
of MWA as a local treatment for HCC and CRLM by
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calculating the rate of incomplete ablation (IA) and local re-
currence (LR) after MWA.
IA of a hepatic tumor was established as the presence of
residual tumor within 1 cm of the ablation site at the first
control imaging with computed tomography (CT) or magnetic
resonance imaging (MRI) after MWA. LR was defined as
tumor recurrence at the site of ablation after at least one im-
aging without evidence for rest tumor. IA and LR are mani-
festations of the same conjuncture of residual tumor cells in
the ablation zone, albeit chronologically segregated by the
interpretation of imaging exams. Therefore, these 2 entities
were combined in order to analyze the possible influence of
risk factors which can be associated with their occurrence.
Recurrence analysis was performed per patient and per tumor.
Secondary endpoints were the assessment of postoperative
outcomes such as operation time, morbidity, and hospital stay,
as well as the identification of possible predictive factors for
IA and LR. The results were compared with the available
literature on percutaneous MWA.
Surgical procedure and follow-up
MWAwas performed by two senior surgeons of the Department
of Hepatopancreatobiliary Surgery, during laparoscopic or open
surgery, under free-hand guidance of non-enhanced ultrasonog-
raphy. They were responsible for the technical planning of the
procedure. Ablations with RFA were performed between 2007
and 2013, but these procedures were excluded from the analysis.
Two different MWA probes were used according to the time
period. Firstly, AMICA 3.0TM microwave system (2450 MHz,
HS Hospital Service, Via Zosimo, Rome, Italy) was used from
May 2013 until December 2015 and afterwards, EmprintTMwith
thermosphere technology cooled tip antenna (2450 MHz,
Medtronic®; Medtronic Parkway, Minneapolis, USA) was used
until the end of the study in May 2018. The ablation probe was
introduced in the liver under free-hand ultrasonography guidance
until the center of the hepatic tumor, after which the ablation was
performed to achieve the calculated ablation zone which should
include an ablative margin of 5–10 mm. Wattage and time were
selected according to the equipment recommendations. Tumor
size was assessed based on the preoperative cross-sectional im-
aging at the point of maximal diameter. In case of a superficial
lesion (location at < 5-mm depth from the liver surface) or a
lesion located nearby a portal pedicle ( < 5-mm distance), the
ablation proceeded with lower power and longer ablation time in
order to achieve the desired ablation volume, so that the risk of
“popcorn effect” with a burst superficial lesion and peritoneal
seeding could be minimized, as well as the risk of biliary thermal
injury in case of a neighboring portal pedicle. Pringle maneuver
diminishes the vascular flow in the portal pedicles and hence
minimizes the “heat-sink” effect in case of a neighboring lesion
but also increases the risk of bile duct injury and subsequent
bilioma by increasing the heating. Therefore, this strategy was
not applied. Vascular proximity was defined as present when a
lesion was located at less than 5 mm of a vascular structure
(hepatic vein or portal pedicle). Follow-up occurred according
to the supervision of the surgeon, hepatologist, or oncologist in
charge, following the existent guidelines. The first contrast-
enhanced computed tomography (CT) or magnetic resonance
imaging (MRI) was planned within 3–6 weeks after the surgery.
All available imaging was reassessed by two dedicated abdom-
inal radiologists.
Statistical analysis
Continuous variables were described with median and inter-
quartile range (IQR), and they were compared using Student’s
t-test in case of a normal distribution; otherwise, Mann-
Whitney U test was applied. Categorical data were described
with counts and percentages. Chi-square test and Fisher’s ex-
act test were used to compare categorical variables.
Generalized estimating equations (GEE) was used to identify
possible prognostic factors associated with LR and IA as a
dichotomous combined outcome: tumor presence in a hepatic
lesion or not. This methodology was used to account for clus-
tering in the data as some of the patients had more than one
lesion and the data was analyzed per lesion. The chosen work-
ing correlation structure was “exchangeable.”Odds ratio (OR)
and 95% confidence interval (CI) were used to interpret the
results. All statistical analyses were performed with IBM®
SPSS® statistics 27.0 (2020, Armonk, New York, USA), ex-
cept for GEE which was performed in open-source R software
[11]. A p-value of < 0.05 was considered statistically
significant.
Results
A total of 128 patients were screened, and 47 patients were
included in the study. Sixty-nine patients were excluded be-
cause of a combined procedure. There was a combination with
liver resections in 58 patients, 5 of whom had an ALPPS
procedure (associating liver partition and portal vein ligation
for staged hepatectomy); in 10 patients, there was a combina-
tion with colorectal resections, 4 of whom with cytoreductive
surgery and HIPEC (hyperthermic intraperitoneal chemother-
apy). One patient had a concomitant esophagectomy. Three
additional patients were excluded because MWA was per-
formed despite clear systemic progression of the disease, be-
cause of reasons specified during the multidisciplinary tumor
board meeting. The baseline characteristics of the study pop-
ulation are shown in Table 1.
CRLM patients had more frequently a previous laparotomy
[13 (77%) vs 2 (7%), p<0.001] and had more often multiple
lesions [11 (65%) vs 5 (17%), p=0.002] which could explain
the longer operation time [155 min (118–223) vs 110 (77–
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141), p=0.001] due to the adhesiolysis and extra ablations
required. With exception of these 3 mentioned features, there
were no major differences between the CRLM and HCC sub-
populations (Table 1). Only 1 patient underwent an open pro-
cedure despite previous laparotomy in 13 (77%) patients with
CRLM and 2 (7%) patients with HCC.
Severe morbidity was observed in 3 patients (Clavien-
Dindo III–IV, 6.4%) with one case of bleeding, one case of
colonic perforation, and one late case of bile duct dilation after
ablation of a central lesion in segment 8, which eventually
required the resection of the hepatic anterior sector, 6 months
after the ablation because of a bile leak and dilation of the bile
ducts in this sector. There was no perioperative mortality.
When we analyze the results per patient (Table 2), the most
frequent found sites of first recurrence were “remote hepatic
recurrence only” (11 cases, 23.9%) and “local recurrence” (10
cases, 21.7%). Median follow-up was 26 months (IQR: 12–
40). The percentage of patients with no recurrence was higher
in the HCC group in comparison to the CRLM group [13
(43.3%) vs 4 (25%), p=0.352]. The median time to local re-
currence was 6 months shorter in the patients with CRLM [6
(2.5-9)] in comparison to the patients with HCC [12 (7-13)]
(p=0.015) (Table 2).
Six out of 30 patients in the HCC cohort (20%) had a liver
transplantation, and in 2 (6.7%) of these patients, although
imaging was not suspect for a local recurrence, pathology
report of the explanted liver still showed residual tumor in
the ablation site.
A total of 70 hepatic lesions were treated (Table 3).
Incomplete ablation rate was 8.6%, and local recurrence rate
was 29.4% on the analysis per tumor, without a significant
difference between CRLM and HCC (Table 3).
Table 1 Clinical characteristics
Characteristic CRLM (n = 17) HCC (n = 30) Total (n = 47) p
% cases 36 64 100 NA
Age
Median, yr (IQR) 62 (52–74) 65 (58–71) 64 (52–72) 0.760
Sex, n (%)
Female 2 (11.8) 8 (26.7) 10 (21.3) 0.289
Male 15 (88.2) 22 (73.3) 37 (78.7)
BMI
Median, kg/m2 (IQR) 24 (22–30) 27 (24–31) 26 (23–30) 0.295
Child-Pugh score, n (%)
A NA 23 (77) NA NA
B NA 7 (23) NA
MELD-score
Median, (range) NA 10 (8–12) NA NA
Location of primary CRC, n (%)
Right-sided 4 (24) NA NA NA
Left-sided 8(47) NA NA
Rectum 5 (29) NA NA
Operation time
Median, min (range) 155 (118–223) 110(77–141) 120 (95–160) 0.001
Previous laparotomy, n (%) 13 (77) 2 (7) 15 (32) <0.001
Approach, n (%)
Open 1 (5.9) 0 (0) 1 (2.1) 0.362
Laparoscopic 16 (94.1) 30 (100) 46 (97.9)
Number of hepatic lesions, n (%)
1 6 (35) 25 (83) 31 (66) 0.002
2 8 (47) 4 (13) 12 (25.5)
3 3 (18) 1 (4) 4 (8.5)
Clavien-Dindo classification, n (%)
I–II 2 (11.8) 1 (3.3) 3 (6.4) 0.792
III–IV 1 (5.9) 2 (6.7) 3 (6.4)
Hospital stay
Median, days (range) 3(3–5) 3 (2–4) 3 (2–4) 0.290
NA not applicable, CRC colorectal cancer, IQR interquartile range
Langenbecks Arch Surg
Multivariable analysis based on GEE showed that vascular
proximity (OR=3.4; 95% CI=1.26–9.22; p=0.016) was a sig-
nificant predictor of the combined outcome IA or LR recur-
rence, while superficial location of the tumor had a protective
effect (OR = 0.32; 95%CI = 0.11–0.96; p=0.041). Also, the
size of the tumor (> 20 mm) showed a tendency to be associ-
ated with higher odds of IA or LR with a marginal significant
p-value (OR = 3.43, 95% CI = 0.88,13.41, p = 0.076)
(Table 4).
Etiology, tumor location in the posterosuperior segments,
and necessity of multiple placement of the ablation probe to
treat the same lesion did not have a predictive value for the
combined outcome LR or IA (Table 4).
Discussion
Surgical possibilities inminimally invasive liver resections are
increasing not only with parenchyma preserving approaches
for CRLM but also with the proposal of liver resections for
HCC in Child B liver cirrhosis [12–14]. As both the local
efficacy of MWA and the technical possibilities of liver resec-
tion increase, while the morbidity of surgery diminishes, this
separation line may blur. In case there are no associated liver
resections planned, the choice between operative ablationwith
laparoscopy and a percutaneous procedure should be posed by
considering their success rates and morbidity.
In this analysis, the feasibility of surgical MWA of hepatic
tumors is corroborated as well as the applicability of laparos-
copy as a safe option after previous open abdominal surgery.
However, the reported rates of IA and LR are higher than
expected (Tables 2 and 3).
Our observed IA rate was 8.6%, and LR rate was 29.4% for
the total of 70 lesions, which is higher than the general results
available in literature (Table 3). In the review by Gang Yang
et al. with inclusion of studies comparing MWA with liver
resection for the treatment of HCC and liver metastases, the
incidence of local tumor recurrence in the MWA group was
16.7% [8]. Operative ablations and percutaneous ablations
with CT and ultrasound guidance were included in the review,
and it was not always mentioned whether the analysis was per
tumor or per patient, warranting a closer analysis to discern
Table 2 Per patient analysis
Characteristic CRLM (n = 17) HCC (n = 30) Total (n = 47) p
First site of recurrence, n (%)
No recurrence 4 (25) 13 (43.3) 17 (37) 0.352
Incomplete ablation 2 (12.5) 3 (10) 5 (10.9)
Local recurrence 3 (18.8) 7 (23.3) 10 (21.7)
Remote hepatic recurrence only 5 (31.3) 6 (20) 11 (23.9)
Intra and extra-hepatic recurrence 2 (12.5) 0 (0) 2 (4.3)
Extra-hepatic recurrence only 0 (0) 1 (3.3) 1 (2.2)
Follow-up
Median, months (IQR) 26 (16–40) 23 (10–41) 26 (12–40) 0.689
Time to local recurrence
Median, months (IQR) 6 (2.5–9) 12 (7–13) 8 (4.5–12) 0.015
IQR interquartile range
Table 3 Per tumor analysis
Characteristic CRLM (n = 31) HCC (n = 39) Total (n = 70) P
% cases 44.3 55.7 100 NA
Tumor size
Median, mm (IQR) 13 (10–20) 18 (10–20) 15 (10–22) 0.602
Vascular proximity, n (%) 7 (24.1) 5 (12.8) 12 (17.6) 0.226
Superficial location, n (%) 14 (48.3) 16 (41) 30 (44.1) 0.552
Tumor in PS segments, n (%) 19 (61.3) 26 (66.7) 45 (64.3) 0.641
Multiple ablation, n (%) 9 (29) 15 (39.5) 24 (34.8) 0.365
Incomplete ablation, n (%) 3 (9.7) 3 (7.7) 6 (8.6) 1
Local recurrence, n (%) 9 (29) 11 (29.7) 20 (29.4) 0.950
PS posterosuperior segments (Sg 1, 4a, 7, 8), NA not applicable, IQR interquartile range
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possible differences [8]. In the study from Takami et al., in-
traoperative MWA of HCC was performed by laparoscopy,
laparotomy, or thoracotomy achieving a local recurrence rate
at 5 years as low as 5.9% for a mean tumor size of 26.9 mm
and after a mean follow-up of 45.9 months [15]. Baker et al.
reported a local recurrence rate of 8.5% after a shorter follow-
up of 10.9 months, and most of the procedures were per-
formed in a laparoscopic fashion. These two reports show
very favorable local control rates after intraoperative ablation
to which our series with mostly laparoscopic MWA compares
inferiorly. In contrast to these results, a retrospective study
with also laparoscopic MWA, comprising 674 patients with
HCC, showed a local tumor progression rate at 1 and 3 years
of 28.6 % and 40.9%, respectively, to which our results com-
pare favorably [16]. Laparoscopic ablations are technically
more demanding, and that could explain a worse local control
in this study by Cillo et al. [16]. In opposition to ablation in
open surgery, there is no free movement of the ablation an-
tenna after defining the passing point of the antenna through
the abdominal wall. In our experience, the establishment of
the trajectory line for the ablation during laparoscopy can be
very challenging and depends on factors such as pneumoperi-
toneum, the angle of approach of the hepatic lesion and rela-
tion to the rib cage, possible need for hepatic mobilization, and
coordination between laparoscopic ultrasound and calculation
of punction trajectory in the liver. These factors may contrib-
ute to an altered approach of the liver anatomy and weaken the
success of ablation by laparoscopy. Guidance systems and
planning software may increase the accuracy of laparoscopic
ablations by helping establish the optimal trajectory of the
ablation probe and target the lesion more efficiently than with
free-hand ultrasound guidance [17].
Studies concerning percutaneous MWA of HCC show a
local recurrence rate between 9.9 and 19 % using CT or ultra-
sound guidance [18–21]. These results are better than our
local recurrence rate per tumor of 29.7% in the present series.
Percutaneous ablations show possible advantages in patients
with a cirrhotic liver and/or concomitant comorbidities in
comparison to an open or laparoscopic procedure by its low
invasiveness and low morbidity, and they offer the possibility
of CT guidance to target lesions barely visible with ultrasound
[7]. Direct percutaneous approach of an hepatic lesion can be
an advantage after extensive liver surgery or in cirrhotic livers,
avoiding cumbersome liver mobilization or the interruption of
collateral circulation. On the other hand, recent studies sug-
gest a possible wider role for liver resection in patients with
HCC and Child B liver cirrhosis [14]. The experience illus-
trated in this retrospective cohort derives from a period when
there was no rigid pre-defined therapeutic pathway and in
which the gold standard of liver resection or at least laparo-
scopic exploration was probably pursued in a more resolute
fashion. Based on recent developments, it seems reasonable to
apply percutaneous CT-guided ablation for the treatment of
small HCC tumors, within Milan criteria as bridge to liver
transplantation [7]. Certain circumstances are not ideal for a
percutaneous approach, and the possibility of offering a lapa-
roscopic exploration remains a useful therapeutic tool like
when the tumor is located near the gallbladder, viscera, or
diaphragm [19]. Superficial tumors are usually to be resected,
but the satisfactory results in the present cohort with ablation
of superficial tumors could be an extra argument to use MWA
in selected cases. We hypothesized that superficial tumor lo-
cation would be a risk factor for IA or LR after MWA due to
the limitations in the use of high energy to prevent a “popcorn
effect,” but it rather proved to be a protective factor against
incomplete local control (Table 4). Apparently, an algorithm
with lower energy and longer ablation time also achieved a
satisfactory local control.
The two most frequent sites of first recurrence in the total
cohort of this trial were “remote hepatic recurrence only”
(23.9%) and “local recurrence” (21.7%) (Table 2). There is
evidence that ablation techniques may promote tumor growth
distant from the primary ablation site through the expression
of cytokines and growth factors promoted by the
Table 4 Analysis of predictive factors for incomplete ablation and local recurrence by generalized estimating equations
Univariable OR (95% CI) Univariable p-value Multivariable OR (95% CI) Multivariable p-value
Etiology (HCC vs CRLM) 0.9 (0.26–3.12) 0.864 0.86 (0.23–3.27) 0.83
Tumor in PS segments 0.69 (0.26–1.83) 0.459 1.31 (0.55–3.15) 0.544
Tumor size ≥ 20mm 2.13 (0.64–7.09) 0.216 3.43 (0.88–13.41) 0.076
Vascular proximity 2.42 (0.91–6.42) 0.076 3.4 (1.26–9.22) 0.016
Superficial location 0.39 (0.14–1.09) 0.073 0.32 (0.11–0.96) 0.041
Multiple ablation 0.83 (0.36–1.9) 0.664 0.66 (0.29–1.48) 0.316
No. of clusters 46
No. of observations 67
PS posterosuperior segments (Sg 1, 4a, 7, 8)
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periablational inflammatory response [22]. A meta-analysis
comparing RFA with surgical resection for CRLM showed
an increased rate of local and “de novo” intrahepatic recur-
rences in the RFA group [3]. A retrospective study involving
imaging review in 59 patients reported a higher growth rate of
new HCC’s after RFA in comparison to the expected rate in
untreated HCC’s [23]. Faster MWA protocols with higher
temperatures may reduce the expression of inflammatory
markers and limit their tumorigenic effects in comparison to
slower RFA or MWA procedures with lower temperatures.
Application algorithms can become even more complex if
one should take into account not only how to obtain the an-
ticipated ablation zone, but also how to limit their undesired
distant effects [22]. It would be interesting to evaluate whether
patients treated for superficial lesions with lower energy and
longer ablation time MWA would develop more intrahepatic
recurrences, but this limited and heterogeneous cohort did not
allow multiple analysis.
The treatment of liver metastases with isolated percutane-
ous ablations is less frequently described in the literature and
shows poorer results concerning local tumor control. The
group from Oxford performed 126 CT-guided percutaneous
ablations in 87 patients with CRLM. With a median tumor
size of 34 mm, the ablation site recurrence rate was 34%
[24]. Alexander et al. analyzed the results of MWA in the
treatment of 64 patients with solitary hepatic malignancies
(HCC, CRLM, other metastases), mostly treated with percu-
taneous CT-guided ablation. With a median tumor size of
between 8 and 12 mm, the 1-year local recurrence rate was
39.8% for HCC and 45.7% for CRLM [25]. These findings
underline the role of biological factors in the local tumor con-
trol. Our series compares favorably with these 2 studies.
Technical skills, local settings, and local expertise remain
important biases, difficult to homogenize between studies. In
the current series, MWA was used in a selected population
with 3 or less hepatic nodules and size inferior to 3 cm, with
up to date MWA generators as a bail-out strategy for tumors
for which resection was deemed cumbersome or too extensive
in relation to the liver function or comorbidities of the patient.
The initial period of RFA and MWA application in our de-
partment was excluded to minimize the effect of learning
curve. The application of laparoscopy in the context of
CRLM seems justified for an abdominal exploration and ul-
trasound evaluation of the liver, which can lead to the identi-
fication of new lesions or lesions thought to be missing after
chemotherapy, clearer identification of the anatomical rela-
tions of the metastases, and possible documentation of perito-
neal metastases. All these findings may lead to an intraopera-
tive modification of the therapeutic strategy from liver resec-
tion to R1 vascular resection or ablation in a laparoscopic or
open fashion [26]. In the context of hepatic recurrence after
extensive liver surgery for CRLM, a percutaneous ablation
may be preferred depending on the size and location of the
lesion, as laparoscopy may not be feasible and an open ap-
proach may not justify the possible morbidity which would
delay the resume of eventual chemotherapy.
Vascular proximity is a known risk factor for local recur-
rence which was confirmed in our study (Table 4) [6].
Sequential ablation with repositioning of the probes is usually
associated with a less predictable result in comparison with
systems where simultaneous multiple applicators are possible
[1]. Repositioning of the probe is also associated with bleed-
ing and tumor seeding [27]. After initial ablation, it can be
difficult to reposition the antenna with ultrasound guidance
and efficiently target the tumor with the postablational arte-
facts. In the present analysis, 34.8% of the tumors were treated
with multiple ablation by repositioning of the probe, but this
was not a risk factor for the combined outcome IA or LR.
Given the retrospective character of this study, the reason for
sequential ablation was not always evident in the operation
report, but an unsatisfying result on ultrasound after the first
ablation could be assumed. CT-guided percutaneous MWA
with intermediate scans to control the position of the probe
and the result of the ablation may offer an advantage. A report
on CT-guided stereotactic navigation MWA showed a good
accuracy, and almost no repositioning of the antenna was
required [27].
After a median follow-up of 26 months (12–40), there
was a significant shorter median time to local recurrence in
the patients with CRLM (6 months, 2.5–9) contrasting with
the HCC patients (12 months, 7–13) (p = 0.015) (Table 2).
There were no local recurrences after 1-year follow-up in
the patients with CRLM, whereas this was still observed in
the HCC group. This could aid to determine the strategy to
follow the patients for the evaluation of local control in the
liver. In CRLM, if findings are not particularly suspicious
upon evaluation after 1 year, it is possibly safe to have a
watch and wait strategy, based on these results which show
an early local recurrence during follow-up. In HCC we
should remain alert for local recurrence until later on.
The fact that imaging techniques are not perfect for the
detection of tumor at the ablation site is illustrated in this
analysis by the diagnosis of ablation site tumor, in 2 of the
6 patients who underwent a liver transplantation for HCC,
after unsuspicious imaging [9].
Limitations of this study are its retrospective character and
its heterogeneity due to the use of 2 different MWA systems
and the joint analysis of CRLM and HCC. Because of the
small sample size, the applicability of subgroup analysis was
limited. On the other hand, this study tries to translate the
reality of MWA application in surgical departments, as being
mostly applied for local control of selected cases of HCC and
CRLM, while surgery remains the mainstay of treatment. In
order to better evaluate the local outcomes of MWA, we se-
lected MWA-only cases, without combination with liver re-
section or other surgeries.
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Future perspectives in the field of local management of
hepatic tumors bring along many technologic developments
and interested parties. The challenge will be to establish a
therapeutic algorithm with all professionals and tools avail-
able, in order to achieve the best treatment possible. The role
of the surgeon, in an era where many of these procedures can
be performed percutaneously using ultrasonography or CT
guidance, is yet to be clarified. The contribution of aiding
software systems, 3D imaging reconstruction, fusion imaging,
and augmented reality are important developments which may
contribute to the improvement of the efficacy of the proce-
dure, allowing a better planning and more accurate guidance
for puncture to obtain the desired trajectory and ablation zone
[17, 28].
Conclusion
MWA is a powerful tool in the armamentarium for the local
treatment of hepatic malignancies. The LR in this study with
mostly laparoscopic MWAwas higher than the rates available
in the literature for percutaneous MWA of HCC but lower
than in the limited studies analyzing isolated percutaneous
MWA of CRLM. Future developments may help address this
matter and clarify the role of each tool in the multimodal
therapeutic algorithm per tumor, in order to improve the
outcomes.
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